511 related articles for article (PubMed ID: 24658078)
1. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
Suragani RN; Cadena SM; Cawley SM; Sako D; Mitchell D; Li R; Davies MV; Alexander MJ; Devine M; Loveday KS; Underwood KW; Grinberg AV; Quisel JD; Chopra R; Pearsall RS; Seehra J; Kumar R
Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
[TBL] [Abstract][Full Text] [Related]
2. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
[TBL] [Abstract][Full Text] [Related]
3. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
Dussiot M; Maciel TT; Fricot A; Chartier C; Negre O; Veiga J; Grapton D; Paubelle E; Payen E; Beuzard Y; Leboulch P; Ribeil JA; Arlet JB; Coté F; Courtois G; Ginzburg YZ; Daniel TO; Chopra R; Sung V; Hermine O; Moura IC
Nat Med; 2014 Apr; 20(4):398-407. PubMed ID: 24658077
[TBL] [Abstract][Full Text] [Related]
4. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
[TBL] [Abstract][Full Text] [Related]
5. Targeting a new regulator of erythropoiesis to alleviate anemia.
Paulson RF
Nat Med; 2014 Apr; 20(4):334-5. PubMed ID: 24710373
[No Abstract] [Full Text] [Related]
6. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway.
De Rosa G; Andolfo I; Marra R; Manna F; Rosato BE; Iolascon A; Russo R
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759740
[TBL] [Abstract][Full Text] [Related]
7. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Langdon JM; Barkataki S; Berger AE; Cheadle C; Xue QL; Sung V; Roy CN
Am J Hematol; 2015 Jan; 90(1):8-14. PubMed ID: 25236856
[TBL] [Abstract][Full Text] [Related]
8. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
[TBL] [Abstract][Full Text] [Related]
9. Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration.
Rochette L; Zeller M; Cottin Y; Vergely C
Pharmacol Ther; 2015 Dec; 156():26-33. PubMed ID: 26523637
[TBL] [Abstract][Full Text] [Related]
10. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
[TBL] [Abstract][Full Text] [Related]
11. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.
Iancu-Rubin C; Mosoyan G; Wang J; Kraus T; Sung V; Hoffman R
Exp Hematol; 2013 Feb; 41(2):155-166.e17. PubMed ID: 23261964
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
[TBL] [Abstract][Full Text] [Related]
13. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
15. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
Claessens YE; Bouscary D; Dupont JM; Picard F; Melle J; Gisselbrecht S; Lacombe C; Dreyfus F; Mayeux P; Fontenay-Roupie M
Blood; 2002 Mar; 99(5):1594-601. PubMed ID: 11861273
[TBL] [Abstract][Full Text] [Related]
16. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
Piron M; Loo M; Gothot A; Tassin F; Fillet G; Beguin Y
Blood; 2001 Jan; 97(2):442-8. PubMed ID: 11154221
[TBL] [Abstract][Full Text] [Related]
17. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
Raimbault A; Itzykson R; Willems L; Rousseau A; Chapuis N; Mathis S; Clauser S; Radford-Weiss I; Bouscary D; Fontenay M; Kosmider O; Bardet V
Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
[TBL] [Abstract][Full Text] [Related]
18. Activin receptor ligand traps in chronic kidney disease.
Jelkmann W
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Chan O; Komrokji RS
Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
[TBL] [Abstract][Full Text] [Related]
20. RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.
Ear J; Huang H; Wilson T; Tehrani Z; Lindgren A; Sung V; Laadem A; Daniel TO; Chopra R; Lin S
Blood; 2015 Aug; 126(7):880-90. PubMed ID: 26109203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
